- Absorption vital component of product effectiveness
- CNSC’s proprietary CiBiDinol technology is cannabidiol made water compatible
- Xceptol products offer CBD in format more in line with body’s natural bioactivity
Gage Cannabis kicked off 2021 with a bang — opening its sixth provisioning center (dispensary) in Michigan and the first in West Michigan (https://ibn.fm/Un9Rc). Gage Cannabis is a leading high-quality craft cannabis brand in Michigan.
“As a lifelong resident of Grand Rapids, I’m thrilled to introduce my hometown to Gage,” said Drew McCarthy, store manager and a local media personality. “While the company prides itself on the three Cs — cannabis, culture and community — in my short time with the company I’ve witnessed a fourth C, caring. I’m proud to be part of a company that cares about its employees, cares about its products and cares about the community.”
At this time, the 4,018-square-foot store is only open to medical marijuana cardholders, with orders available for curbside pick-up only. The store offers more than 40 exclusive strains of flower in addition to a variety of pre-rolls, edibles, concentrates, topicals, tinctures, CBD products, accessories and even apparel.
Gage has a single focus: to curate the highest-quality cannabis experience possible for its consumers (https://ibn.fm/mItNr). The company accomplishes this by growing its own plants in small batches using 100% hydroponic cultivation methods for sustainable and responsible operations. Every plant is handpicked, and then every plant undergoes Gage’s proprietary drying, trimming and curing process, with each step deliberately designed to deliver the best flower possible.
Gage selected Michigan to start its operations based on the state’s fast-growing legal cannabis market and consumer habits. In 2018, Michigan became the 10th state to legalize the recreational use of cannabis. In light of such favorable market dynamics, Gage opened its first medical provisioning center, or dispensary, in 2019. The company now has 13 medical or adult-use locations open or in the works, with an additional 10+ planned to open this year.
About Gage
Gage Cannabis Company is innovating and curating the highest-quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the company’s founding partners have successfully built and grown operations with federal and state licenses including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for 19 Class C cultivation licenses, three processing licenses and 13 provisioning centers (dispensaries).
For more information, visit the company’s website at www.GageUSA.com.
NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis are available in the company’s newsroom at https://ibn.fm/GAGE
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has engaged the services of San Diego-based investor relations firm Torrey Hills Capital, Inc. to increase awareness of its products with an informed investor audience in both the U.S. and Canadian marketplaces.
Torrey Hills Capital is a leading investor and financial PR firm that specializes in small and microcap companies. Formed in 1998, the firm offers considerable expertise and experience in corporate communications, investor relations, non-deal roadshows, as well as other market support activities (https://ibn.fm/8cnR8).
Torrey Hills Capital will provide Imagin Medical with dedicated market awareness and investor relations services that will be overseen by Cliff Mastricola, founder and principal of the firm. Mastricola has extensive experience in advising and developing corporate finance strategies, especially debt and equity capital-related issues, as well as mergers and acquisitions, recapitalizations, valuations and helping private companies go public.
The agreement between Imagin and Torey Hills is subject to regulatory acceptance of applicable filings with the CSE. Signed for an initial period of three months at a monthly rate of $7,000, the agreement can be automatically extended if both parties are satisfied with the terms and achieved progress. Imagin also agreed to a one-time grant of 100,000 incentive stock options at a price of $0.49 (C$0.62) per share for a three-year period.
By contracting Torrey Hills Capital, Imagin Medical plans to increase public and investor awareness of its innovative imaging technology, the i/Blue Imaging System), that the company expects will establish a new standard of care in visualizing cancer during minimally invasive procedures. The company’s initial focus is bladder cancer, the sixth most prevalent forms of cancer in the United States and the most expensive one to treat, while also having one of the highest recurrence rates (https://ibn.fm/KdZpt).
The current standard of visualizing bladder cancer during surgery uses white light illumination, which is especially effective when it comes to visualizing cancerous tumors protruding above the bladder wall. However, with this method flat tumors look the same as normal tissue. This issue is successfully overcome with the use of blue light. The problem, however, is that blue light cannot be used in real-time during surgery, and requires surgeons to constantly switch back and forth between white and blue light images to get perspective.
The proprietary i/Blue Imaging System(TM) addresses the limitations surgeons face in this regard by simultaneously displaying both white-light and blue-light images side by side, in real time. Additionally, the technology is highly versatile and can be attached to most endoscopes on the market, which means hospitals would be able to adopt the innovative visualization system without having to replace their current instruments, resulting in significant cost savings.
According to Imagin Medical, this technology has the potential to revolutionize the current standard of care for bladder cancer patients and help position the company as a leading provider of effective solutions in the global bladder cancer market, which is expected to reach $4.71 billion by 2026 (https://ibn.fm/tTWOf). Imagin Medical also intends to expand its technology for multiple endoscopic procedures in the future, including laparoscopic, colorectal and thoracic procedures that use a variety of contrast agents and illumination sources.
For more information, visit the company’s website at www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
Cannabis plays a key role in MAZAKALI’s mission — in 2016 the company began working specifically to help investors place capital and to help companies raise capital. MAZAKALI’s GreenPapers(R) inform investors and operators through insights into deep trends in the cannabis complex, predicting in 2017 that significant federal reform would take place this year with a Democratic victory in the White House.
“We had been following public opinion polls on (cannabis) legalization and noticed a fairly precipitous decline in the opposition to legalization. As an example, from 2007 through (20)17 we saw opposition decline from 60 to 40 percent and support increase even more, from 30 to nearly 60 percent,” MAZAKALI founder and CEO Sumit Mehta said during an interview with Jeremy Neilson, CEO of Assure (https://ibn.fm/ZVSkT).
“We then looked at other states-led rights issues that eventually became legal at a federal level and we saw fairly similar trajectories,” Mehta added. “We saw a meaningful uptick in the states that were passing cannabis legalization measures between 2015 and 2017, and knew that the majority of Americans would soon have legal access to this plant with countless stories to share about its medical impact. We expected that this would further bolster the public support that was building, fueled further as media was also becoming far less reticent to cover this increasingly destigmatized topic.”
Cannabis is currently legal for medical use in 35 U.S. states and permitted for adult-use in 15 states (https://ibn.fm/W3Bw1). Its use has been adopted by a wide age range of consumers, particularly as older populations turn to cannabidiol (“CBD”) for over-the-counter pain relief and sleep aids (https://ibn.fm/9kTlt).
In further support for investor confidence, observers have noted that President Biden appears to be stocking his cabinet with several key cannabis-friendly advisers. He has named a strong supporter of cannabis legalization as his nominee to lead the Democratic National Committee (“DNC”) (https://ibn.fm/Miclc).
“It is likely that Cannabis will prove to be the best performing asset class over the next decade…Hemp will prove to be a major contribution to farmer livelihood as well as industrial and economic output, with the Cannabis complex likely a trillion-dollar market in the making,” MAZAKALI states as part of its advisory profile (https://ibn.fm/q2uwE).
For more information, visit the company’s website at www.MAZAKALI.com.
NOTE TO INVESTORS: The latest news and updates relating to MAZAKALI are available in the company’s newsroom at https://ibn.fm/MAZAKALI
The COVID-19 pandemic has revealed flaws in the U.S. health-care system, including flaws that require patients and caregivers to take a more active and educated role. United Medical Equipment Business Solutions Network (“UME”) provides reliable resources and solutions to help providers work more proficiently, health-care systems work smarter, and patients live healthier lives.
“This pandemic is a watershed moment in American history, one we must seize upon to fix the most glaring problems in our health system. We can’t ignore one health crisis for the sake of another,” wrote American Medical Association CEO and executive VP James L. Madara, MD, in a recent article (https://ibn.fm/ixqFL).
A few of the flaws that Madara points out are unequal treatment based on location, ethnicity, affordability and access to health insurance. He calls for collaboration to disrupt the status quo and create a new, affordable, efficient and accessible system for all. However, he notes, many obstacles interfere with patient care.
Communication and a lack of education around the medicines administered play a large part in failed care plans, dosage errors, no-adherence and readmittance to hospitals. Not every patient has easy access to needed education, which is something UME is working to change.
When patients and their doctors communicate clearly and openly with one another, the better the level and execution of a care plan occurs. When communication is clear, the patient or caregiver better understands the health condition and the treatment options. Proper education around all over-the-counter and prescribed doses is essential to avoid missed, skipped or willfully ignored care plans.
Medication management is an essential part of any treatment plan. When a patient or caregiver understands the purpose, dosage, side effects and other unique qualities of the medications being prescribed, they have a higher success rate of follow through. Aging individuals need caregivers who also have access to this education, whether those caregivers are able to attend doctor appointments or not.
Collaboration between a patient and physician is essential to improve the patient’s health. The physician needs to know all medications being taken, including over-the-counter, herbal and alternatives, because they may interact with what is prescribed. The patient needs to be informed about what they are taking, as well as why and how the medications work.
A lack of adherence can lead to serious problems that include a worsening of disease, possible death and increased costs to both the patient and the overall health-care system. Poor provider-patient communication and inadequate knowledge about a drug are two large barriers in medication adherence (https://ibn.fm/MVVWn). United Medical has developed a solution to address these barriers: a free medication management app available for download on the Apple App Store and Google Play.
The free seven-day trial version of the Medication Management app has a medication dictionary with up-to-date information on medications. The dictionary provides an image and description of the physical drug as well as an overview, side effects to look for, interactions with food and other drugs, and more. The app also comes with a pill identifier and converters for weight, temperature, volume, height and dosage. The company’s newest, highly asked for feature — Medication Log-Reminder — allows users to log all their medications in one convenient location and set reminders to take their medications. The app is protected by HIPAA compliance for PHI. Subscriptions are also available that allow the user to access telehealth and additional services for a small monthly fee.
For more information, visit the company’s website at www.UnitedMedSolutions.com.
NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed
August 28, 2026
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising. Gold’s relationship with interest rates has long been one of the most closely watched dynamics in precious-metals markets. Because gold does not generate interest or dividends, higher real yields can increase the opportunity cost of holding the metal and, […]
Rotate your device 90° to view site.